| 期刊簡介 | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱 | Chinese Journal of Cancer (According to the latest JCR data, this journal is not indexed in the JCR.) LetPub Score 4.3
50 ratings
Rate
Reputation 4.7 Influence 3.0 Speed 9.2 | ||||||||||||||||
| 期刊簡稱 | CHIN J CANCER | ||||||||||||||||
| ISSN | 1000-467X | ||||||||||||||||
| h-index | 42 | ||||||||||||||||
| CiteScore |
| ||||||||||||||||
| 自引率 (2023-2024) | N.A.自引率趨勢 | ||||||||||||||||
| 掲載範囲 |
| ||||||||||||||||
| 官方網站 | http://cjcjournal.biomedcentral.com/ | ||||||||||||||||
| 在線稿件提交 | https://www.editorialmanager.com/chjc/default.aspx | ||||||||||||||||
| 開放訪問 | Yes | ||||||||||||||||
| 出版商 | BMC | ||||||||||||||||
| 主題領域 | ONCOLOGY | ||||||||||||||||
| 出版國/地區 | United Kingdom | ||||||||||||||||
| 發行頻率 | |||||||||||||||||
| 創刊年 | 0 | ||||||||||||||||
| 每年文章數 | 0每年文章數趨勢 | ||||||||||||||||
| 黃金OA百分比 | 0.00% | ||||||||||||||||
OA Related Info | APC: Yes（ GBP1370; ） APC waiver：Check Notes Other charges: No Keywords: cancer Useful LinksAims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review | ||||||||||||||||
| Web of Science 四分位 （ 2023-2024） | WOS Quartile: Q0 N/A | ||||||||||||||||
| 索引 (SCI or SCIE) | |||||||||||||||||
| 鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1000-467X%5BISSN%5D | ||||||||||||||||
| 平均審稿時間 * | 來自出版商的數據: 來自作者的數據: 12 Weeks | ||||||||||||||||
| 競爭力 * | 來自作者的數據: | ||||||||||||||||
| 參考鏈接 |
| ||||||||||||||||
| *所有的審稿過程指標，如接受率和審稿速度，僅限於用戶提交的稿件。因此，這些指標可能無法準確反映期刊的競爭力或速度。 | |||||||||||||||||
| 首頁 上一頁 1 下一頁 末頁 (頁 | |
| [Chinese Journal of Cancer] 的評論 | 撰寫評論 |
| 作者: drofcancer@yahoo.com 領域: 医药科学 審稿時間: 1.0 month(s) 結果: 修改後接受 撰寫評論 |
2021-01-05 04:02:16 評論於 Meta-Analysis Of Positive Mutation EGFR For Erlotinib, Gefitinib Or Icotinib Plus Chinese Medicine Versus Erlotinib, Gefitinib Or Icotinib Alone In Patients With Non Small Cell Lung Cancer, A Regional Study East China  (0) 讚！ | drofcancer@yahoo.com  |
| 作者: drofcancer@yahoo.com 領域: 医药科学 審稿時間: 1.0 month(s) 結果: 修改後接受 撰寫評論 |
2021-01-05 04:02:15 評論於 Meta-Analysis Of Positive Mutation EGFR For Erlotinib, Gefitinib Or Icotinib Plus Chinese Medicine Versus Erlotinib, Gefitinib Or Icotinib Alone In Patients With Non Small Cell Lung Cancer, A Regional Study East China (0) 讚！ | drofcancer@yahoo.com |
| 作者: drofcancer@yahoo.com 領域: 医药科学 審稿時間: 1.0 month(s) 結果: 修改後接受 撰寫評論 |
2021-01-05 04:01:24 評論於 Meta-Analysis Of Positive Mutation EGFR For Erlotinib, Gefitinib Or Icotinib Plus Chinese Medicine Versus Erlotinib, Gefitinib Or Icotinib Alone In Patients With Non Small Cell Lung Cancer, A Regional Study East China (0) 讚！ | drofcancer@yahoo.com |
| 作者: lry 領域: 医药科学 審稿時間: 1.0 month(s) 結果: 修改後接受 撰寫評論 |
2017-09-26 12:32:51 評論於 The quality of contributing manuscripts has been greatly improved after the journal partnered with BioMed Central Publishing Group. The IF is gradually increasing, and it is expected to exceed 5 next year. It is the number one oncology journal in China. Papers must have a certain degree of novelty and of certain quality to be considered here, but this journal should be easier than other IF 4-5 journals to get accepted. (1) 讚！ | lry |
| 首頁 上一頁 1 下一頁 末頁 (頁 | |
Contact us
